All In Biotech

Drug Trial Radar · NCT06697184

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Jan 23, 2025

Primary completion

Nov 30, 2029

Study completion Nov 30, 2032

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Conditions

  • Chronic Lymphocytic Leukemia
  • CLL
  • Mantle Cell Lymphoma
  • MCL

Interventions

  • SonrotoclaxDrug

    Administered orally

  • ZanubrutinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience Tumor Lysis Syndrome (TLS)Time frame: Up to approximately 4 months

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia · Recruiting

  • Genesiscare St Andrews

    Adelaide, South Australia, Australia · Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Rockingham Hospital

    Cooloongup, Western Australia, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia Celular

    São Paulo, Brazil · Recruiting

  • Hospital Santa Rita de Cassia Afecc

    Vitória, Brazil · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Chu Dijon

    Dijon, France · Recruiting

  • Chu Montpellier Hopital Saint Eloi

    Montpellier, France · Recruiting

  • Iuct Oncopole

    Toulouse, France · Recruiting

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Recruiting

  • St Jamess University Hospital

    Leeds, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.